Corautus Genetics Inc. Elects Robert T. Atwood, Chief Financial Officer, Executive Vice President and Secretary, to Board of Directors.Business Editors/Health/Medical Writers ATLANTA--(BUSINESS WIRE)--Jan. 9, 2004 Corautus Genetics Inc. (AMEX AMEX See: American Stock Exchange : CAQ CAQ Center for Audit Quality (New York, New York) CAQ Certificat d'Acceptation du Quebec CAQ Computer-Aided Quality Assurance CAQ Certificate of Added Qualification CAQ Computer-Aided Quality Control CAQ Condition Adverse to Quality ) elected Robert T. Atwood to its Board of Directors at a fourth quarter Board of Director's meeting. Mr. Atwood joined Vascular Genetics, the predecessor of Corautus, in January 2002. Mr. Atwood was previously Executive Vice President and Chief Financial Officer of First Union Corporation (now Wachovia Corporation) and prior to that he was with Deloitte & Touche for twenty-nine years. In announcing the appointment, Richard Otto, Chief Executive Officer and President of Corautus, commented, "Bob's talents are crucial to building long term value for our shareholders, and the development and commercialization of our exciting gene transfer therapeutic, VEGF-2, to combat cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . Bob has been instrumental in helping us achieve our current success, including our alliance with Boston Scientific and our upcoming Phase IIb trial, and preparing us for a bright future. I am delighted Bob accepted this additional position." About Corautus Genetics Corautus Genetics Inc. is a clinical stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of severe cardiovascular and peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. . Corautus is currently developing and testing a gene transfer product using the Vascular Endothelial Growth Factor Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). 2 (VEGF-2) gene to promote therapeutic angiogenesis in ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic muscle. In July 2003, Corautus entered into a series of agreements with Boston Scientific Corporation to fund, develop, commercialize and distribute the VEGF-2 gene therapy products. Forward Looking Statement This press release may contain forward-looking statements made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations or our financial condition, benefits from the alliance with Boston Scientific, synergies from the merger between GenStar and Vascular Genetics, research, development and commercialization of our product candidates, anticipated trends in our business, approval of our product candidates and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risks discussed in Corautus' Annual Report on Form 10-K (File No. 001-15833) filed March 28, 2003, which are incorporated by reference into this press release. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion